WO2005039606A3 - Moderating the effect of endotoxins - Google Patents

Moderating the effect of endotoxins Download PDF

Info

Publication number
WO2005039606A3
WO2005039606A3 PCT/EP2004/011416 EP2004011416W WO2005039606A3 WO 2005039606 A3 WO2005039606 A3 WO 2005039606A3 EP 2004011416 W EP2004011416 W EP 2004011416W WO 2005039606 A3 WO2005039606 A3 WO 2005039606A3
Authority
WO
WIPO (PCT)
Prior art keywords
effects
moderating
endotoxins
effect
oral composition
Prior art date
Application number
PCT/EP2004/011416
Other languages
French (fr)
Other versions
WO2005039606A2 (en
Inventor
Irene Corthesy-Theulaz
Grigorios Fotopoulos
Gabriela Bergonzelli
Original Assignee
Nestec Sa
Irene Corthesy-Theulaz
Grigorios Fotopoulos
Gabriela Bergonzelli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34354433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005039606(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to JP2006534666A priority Critical patent/JP4918361B2/en
Priority to US10/595,397 priority patent/US8216605B2/en
Priority to AT04790307T priority patent/ATE435022T1/en
Priority to ES04790307T priority patent/ES2328149T5/en
Priority to BRPI0415385-5A priority patent/BRPI0415385A/en
Application filed by Nestec Sa, Irene Corthesy-Theulaz, Grigorios Fotopoulos, Gabriela Bergonzelli filed Critical Nestec Sa
Priority to EP04790307.5A priority patent/EP1675601B2/en
Priority to DE602004021831T priority patent/DE602004021831D1/en
Priority to CA002542448A priority patent/CA2542448A1/en
Priority to DK04790307.5T priority patent/DK1675601T4/en
Publication of WO2005039606A2 publication Critical patent/WO2005039606A2/en
Publication of WO2005039606A3 publication Critical patent/WO2005039606A3/en
Priority to IL174978A priority patent/IL174978A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to the use of an oral composition comprising meat extract and peptones, separately or in combination, in the manufacture of an oral composition to treat the effects of infection by pathogenic bacteria such as Clostridium difficile. Such effects may include the failure of the integrity of the gut epithelial cells and diarrhoea as well as other COX-2 mediated effects.
PCT/EP2004/011416 2003-10-13 2004-10-12 Moderating the effect of endotoxins WO2005039606A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DK04790307.5T DK1675601T4 (en) 2003-10-13 2004-10-12 Moderation of the effect of enterotoxins
US10/595,397 US8216605B2 (en) 2003-10-13 2004-10-12 Moderating the effect of endotoxins
AT04790307T ATE435022T1 (en) 2003-10-13 2004-10-12 MODIFICATION OF THE EFFECTS OF ENDOTOXINS
ES04790307T ES2328149T5 (en) 2003-10-13 2004-10-12 Moderation of the endotoxin effect
BRPI0415385-5A BRPI0415385A (en) 2003-10-13 2004-10-12 moderation of endotoxin effect
JP2006534666A JP4918361B2 (en) 2003-10-13 2004-10-12 Mitigation of endotoxin action
EP04790307.5A EP1675601B2 (en) 2003-10-13 2004-10-12 Moderating the effect of endotoxins
DE602004021831T DE602004021831D1 (en) 2003-10-13 2004-10-12 Modification of the action of endotoxins
CA002542448A CA2542448A1 (en) 2003-10-13 2004-10-12 Moderating the effect of endotoxins
IL174978A IL174978A0 (en) 2003-10-13 2006-04-11 Moderating the effect of endotoxins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03023016.3 2003-10-13
EP03023016 2003-10-13

Publications (2)

Publication Number Publication Date
WO2005039606A2 WO2005039606A2 (en) 2005-05-06
WO2005039606A3 true WO2005039606A3 (en) 2005-09-15

Family

ID=34354433

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/011416 WO2005039606A2 (en) 2003-10-13 2004-10-12 Moderating the effect of endotoxins

Country Status (17)

Country Link
US (1) US8216605B2 (en)
EP (1) EP1675601B2 (en)
JP (1) JP4918361B2 (en)
CN (2) CN1886144A (en)
AR (1) AR047763A1 (en)
AT (1) ATE435022T1 (en)
BR (1) BRPI0415385A (en)
CA (1) CA2542448A1 (en)
DE (1) DE602004021831D1 (en)
DK (1) DK1675601T4 (en)
ES (1) ES2328149T5 (en)
IL (1) IL174978A0 (en)
MY (1) MY140220A (en)
PT (1) PT1675601E (en)
TW (1) TW200520696A (en)
WO (1) WO2005039606A2 (en)
ZA (1) ZA200603824B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508342A (en) * 2003-10-13 2007-04-05 ネステク ソシエテ アノニム Mitigation of endotoxin action
CN113729228A (en) * 2020-05-29 2021-12-03 安琪纽特股份有限公司 Composition for preventing or improving diarrhea, and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US177534A (en) * 1876-05-16 Improvement in meat-extracts
US20020155126A1 (en) * 1999-08-13 2002-10-24 Yoshiharu Shirasu Pharmacological composition containing yeast cell wall fraction

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595590A (en) 1984-01-17 1986-06-17 Laboratoires Biocodex Method for preventing or treating pseudo-membranous colitis
JPS61236727A (en) 1985-04-12 1986-10-22 Advance Res & Dev Co Ltd Cariostatic and antiperiodontosis agent
JP2805490B2 (en) 1989-02-07 1998-09-30 雪印乳業株式会社 Bacterial toxin neutralizer
CN1056750C (en) * 1993-12-10 2000-09-27 济南三株药业有限公司 Sanzhu oral liquid and its preparing method
US5550106A (en) 1994-03-04 1996-08-27 Bristol-Myers Squibb Company Low buffer nutritional composition
RU2168915C2 (en) * 1996-03-19 2001-06-20 Алтайский научно-исследовательский проектно-технологический институт животноводства Meat product for infant food
US7374753B1 (en) * 1997-06-03 2008-05-20 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
US6368591B2 (en) * 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
JP2001008636A (en) 1999-06-30 2001-01-16 Tanabe Seiyaku Co Ltd Feed composition for preventing infectious disease
JP3307627B2 (en) 2000-02-09 2002-07-24 オク タイン A method for producing a group of cytochalasin-like substances from the yeast Zygosaccharomycesrouxii.
NL1014380C2 (en) † 2000-02-14 2001-08-15 Friesland Brands Bv Intestinal wall-strengthening food.
JP2002080351A (en) 2000-09-07 2002-03-19 Natl Fedelation Of Agricult Coop Assoc Immunopotentiator
SE0003958D0 (en) * 2000-10-31 2000-10-31 Biogaia Fermentation Ab Method for growth of microorganisms
FI114895B (en) * 2001-05-14 2005-01-31 Suomen Rehu Oy Additive for food
US20040176320A1 (en) † 2001-06-29 2004-09-09 Jari Natunen Use of at least one glycoinhibitor substance
ATE428430T1 (en) † 2002-06-28 2009-05-15 Glykos Finland Oy THERAPEUTIC COMPOSITIONS FOR USE IN THE PROPHYLAXIS OR TREATMENT OF DIARRHEA
PT1565547E (en) * 2002-06-28 2008-11-03 Puleva Biotech Sa Probiotic strains, a process for the selection of them, compositions thereof, and their use
ATE339114T1 (en) * 2002-07-23 2006-10-15 Wrigley W M Jun Co ENCAPSULATED FLAVORS AND CHEWING GUM WITH IT
JP2007508342A (en) 2003-10-13 2007-04-05 ネステク ソシエテ アノニム Mitigation of endotoxin action

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US177534A (en) * 1876-05-16 Improvement in meat-extracts
US20020155126A1 (en) * 1999-08-13 2002-10-24 Yoshiharu Shirasu Pharmacological composition containing yeast cell wall fraction

Also Published As

Publication number Publication date
US20070122453A1 (en) 2007-05-31
ES2328149T3 (en) 2009-11-10
JP4918361B2 (en) 2012-04-18
CA2542448A1 (en) 2005-05-06
CN1886144A (en) 2006-12-27
MY140220A (en) 2009-12-31
AR047763A1 (en) 2006-02-22
IL174978A0 (en) 2006-08-20
JP2007527410A (en) 2007-09-27
EP1675601B2 (en) 2013-04-10
DK1675601T3 (en) 2009-11-09
ES2328149T5 (en) 2013-07-12
ZA200603824B (en) 2007-07-25
BRPI0415385A (en) 2006-12-12
DK1675601T4 (en) 2013-05-06
TW200520696A (en) 2005-07-01
CN102319417B (en) 2014-08-13
US8216605B2 (en) 2012-07-10
ATE435022T1 (en) 2009-07-15
WO2005039606A2 (en) 2005-05-06
PT1675601E (en) 2009-08-31
CN102319417A (en) 2012-01-18
EP1675601B1 (en) 2009-07-01
DE602004021831D1 (en) 2009-08-13
EP1675601A2 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
WO2008036932A3 (en) Compositions and methods comprising boswellia species
TW200603834A (en) Film products having controlled disintegration properties
MY151984A (en) Non-anticoagulant polysaccharide compositions
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
NZ595749A (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2007092622A3 (en) Compositions and methods for treating bone
WO2008085221A3 (en) Therapeutic use of cd31 expressing cells
CY1107399T1 (en) FORM OF ADMINISTRATION OF ORAL CONTENT
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MY152710A (en) Oral compositions containing extracts of garcinia mangostana l. and related methods
WO2006128089A3 (en) Compositions and methods for treating tissue
WO2007144779A3 (en) Compositions comprising porphyra and methods of making and using thereof
ATE505955T1 (en) COFFEE COMPOSITION
WO2008064345A3 (en) Microorganism killing compounds
TW200745132A (en) Novel, acyclically substituted furopyrimidine derivatives and use thereof
WO2008016730A3 (en) Compositions and methods for reducing cellular fat
WO2008033556A3 (en) High pressure treatment of proteins for reduced immunogenicity
TW200626073A (en) Activated globular protein and its use in edible compositions
WO2007134118A3 (en) Protein based composition and methods of using same
DE502005008925D1 (en) SUBSTITUTED NONADESPIPEPTIDES
IL194353A0 (en) Lysobactin amides
HK1112928A1 (en) Cspcna isoform modifications and uses thereof
TW200640858A (en) Substituted pyrroles, compositions containing them, method of manufacture and use
WO2006129092A3 (en) Use of bacteriophage in medicaments
WO2006123164A3 (en) Lps-binding and bactericidal cytokines and interferons

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480035018.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 174978

Country of ref document: IL

Ref document number: 2004790307

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2542448

Country of ref document: CA

Ref document number: 1974/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006534666

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12006500762

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2006/03824

Country of ref document: ZA

Ref document number: 200603824

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 2004790307

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007122453

Country of ref document: US

Ref document number: 10595397

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0415385

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10595397

Country of ref document: US